Nature Communications (Nov 2017)
Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling
- Yassine Sassi,
- Petros Avramopoulos,
- Deepak Ramanujam,
- Laurenz Grüter,
- Stanislas Werfel,
- Simon Giosele,
- Andreas-David Brunner,
- Dena Esfandyari,
- Aikaterini S. Papadopoulou,
- Bart De Strooper,
- Norbert Hübner,
- Regalla Kumarswamy,
- Thomas Thum,
- Xiaoke Yin,
- Manuel Mayr,
- Bernhard Laggerbauer,
- Stefan Engelhardt
Affiliations
- Yassine Sassi
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Petros Avramopoulos
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Deepak Ramanujam
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Laurenz Grüter
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Stanislas Werfel
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Simon Giosele
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Andreas-David Brunner
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Dena Esfandyari
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Aikaterini S. Papadopoulou
- VIB Center for the Biology of Disease, VIB
- Bart De Strooper
- VIB Center for the Biology of Disease, VIB
- Norbert Hübner
- Cardiovascular and Metabolic Sciences, Max-Delbrüeck-Center for Molecular Medicine in the Helmholtz Association (MDC)
- Regalla Kumarswamy
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Thomas Thum
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Xiaoke Yin
- King’s British Heart Foundation Centre, King’s College London
- Manuel Mayr
- King’s British Heart Foundation Centre, King’s College London
- Bernhard Laggerbauer
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- Stefan Engelhardt
- Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
- DOI
- https://doi.org/10.1038/s41467-017-01737-4
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 11
Abstract
MicroRNA-29 is known to reduce collagen production in fibroblasts thereby inhibiting fibrosis in various organs. Here, Sassi et al. show that miR-29 can also enhance fibrotic signalling and pathological hypertrophy of the heart through its action in cardiomyocytes.